Recombinant DNA Technology Market Grow Owning to Innovations in Technology

Recombinant DNA (rDNA) technology is a novel technique which have led to the advances in a number of different fields such as drug development, agriculture and research. Recombinant DNA technology has introduced new classes of organism namely genetically modified organism (GMO) or living modified organism (LMO). It can develop genetically modified crops (BT cotton), cloned animals, bio pesticides, biofuel, and gene therapy successfully. rDNA technology has triggered the biopharmaceutical industries towards the development of various rDNA products such as CAR-T cell therapy and bispecific and monoclonal antibodies in turn favoring the growth of recombinant DNA technology market. Also, the gene editing system CRISPR holds a great potential for the development of vaccines and drugs, as they play a major role in stability and enhancement of immunity.
Get HOLISTIC Request Sample Copy Of This Business Report:
www.coherentmarketinsights.com/insight/request-sample/893
Market Dynamics
Rapid technological advancements in the field of genetic engineering to deliver highly efficient therapeutics for disease management and in the field of agriculture are major driving factors for growth of recombinant DNA technology market. For instance, Bac-to-Bac Baculovirus Expression Systems offers a quick and efficient method to produce recombinant baculovirus and can express the desired genes in insect cells and provide high yields of recombinant protein that speeds up the cloning reaction as compared to the time-consuming restriction enzyme cloning, which takes 2–3 days. Also, in 2016, a BioAg Alliance was formed between Monsanto and Novozymes A/S, to improve crop harvests by using products containing naturally-occurring microbes to boost agricultural productivity and expand its product portfolio. However, the adoption of non-biologic therapeutics and higher complexity of the genetically engineered products such as stability of the cell lines, requirement of skilled professionals, and optimum temperature are the factors hindering the market growth.
Detailed Segmentation:
Global Recombinant DNA Technology Market, By Product Type:
Recombinant Protein Drugs
Insulin
Human Growth Hormone
Erythropoietin
Interferon
Blood Factors
Colony Stimulating Factors
Fusion Proteins
Others
The major manufacturers are involved in strategic collaborations with leading biopharmaceutical companies and research institutes for the development of novel therapeutics based on recombinant DNA technologies. Such strategic collaborations in market are expected to create conducive environment for growth of the global recombinant DNA technology market in the near future. For instance, in August, 2017, Sanofi Pasteur acquired Protein Sciences, with a strategy to add a promising product to its vaccine portfolio- Flublok (Influenza Vaccine), which is the only U.S. Food and Drug Administration (FDA) approved recombinant protein-based influenza vaccine. In 2014, Pfizer, Inc. and the Massachusetts Institute of Technology (MIT) collaborated to advance drug discovery and development technologies through recombinant DNA technology to transform the treatment of various diseases.
Also, in 2015, the National Academy of Sciences and the National Academy of Medicine launched a major initiative to guide new research involving human gene editing technologies, such as CRISPR-Cas9, which could lead to the emergence of promising new treatments for disease.
Major players operating in the global recombinant DNA technology market are Thermo Fisher Scientific, Inc., Biogen, Inc., Sanofi Pasteur, Merck & Co., Inc., Pfizer, Inc., Profacgen, Amgen, Inc., and Monsanto Company.
Moreover, the research organizations are launching initiatives and providing research grants for the development of novel therapeutics, which is expected to propel growth of the recombinant DNA technology market over the forecast period. For instance, in March 2017, the University of Pennsylvania received US$ 16.3 million grants from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a recombinant DNA technology-based HIV vaccine. In 2015, Translational Genomics Research Institute (TGen) and Baylor Research Institute (BRI) collaborated to focus on accelerating early detection and treatments for patients by developing personalized vaccines for a wide range of conditions such as infectious disease, cardiovascular, diabetes, neurology, and metabolic diseases.

Comments

Post a Comment

Popular posts from this blog

Cough Suppressant Drugs Market Widespread Research and Fundamental study to 2026

A cough is a most common symptom of various upper and lower respiratory tract infections. It affects a large proportion of the population leading them to seek medical attention. According to the data published by Journal of the Association of Physicians of India in 2016, cough was identified as the sixth most common reason for hospital outpatient department visits. Cough suppressants, also known as antitussives, are medications that help to suppress cough. Some of the examples of cough suppressants are Dextromethorphan, Codeine, Noscapine, Butamirate, Benzonatate, and Pholcodine. Dextromethorphan and Codeine are the most common and widely used cough suppressant in market. Key players operating in the global cough suppressant drugs market include Perrigo Company plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and
Read more

Medical Disposables Market to Witness a Pronounce Growth by 2026

Medical disposables are products that are used in hospitals or in various medical fields for prevention of infections and for safety measures to meet the medical standards. The medical disposables are important to lower the risk of cross-contamination and infections that is a primary aim of healthcare professionals and governments globally. Medical disposables includes conventional syringes, disposable medical catheters, isolation gowns, procedure kits and trays, blood glucose tes t strips, and wound care products. The medical disposables are the essential component of every hospital and they have one time usage and need to be disposed after use. Medical disposables are used in surgery, drug and fluid delivery, wound management, diagnostic testing, patient examination, incontinence management, sterilization, and to reduce the discomfort of patient. The need of safety and prevention from infections for the various medical fields such as surgical wear, hygiene, anesthesia and ped
Read more

Idiopathic Pulmonary Fibrosis Treatment Market Evolving Industry Trends and key Insights by 2026

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease distinguished by progressive and irreversible reduction in lung function characterized by thickening and damaging of the walls of the air sacs (called alveoli). Common symptoms include, dry cough, gradual onset of shortness of breath, nail clubbing, and fatigue. Other symptoms are weight loss and muscle and joint pain. Further complications include, hypertension, heart failure, pulmonary embolism or pneumonia. Major factors causing damage to the lungs include, acid reflux from stomach, certain viruses such as Epstein Barr virus and herpes virus or environmental factors such as breathing in dust such as silica dust, asbestos fibers, hard metal dust, and coal dust. Treatments for idiopathic pulmonary fibrosis (IPF) include, oxygen therapy, pulmonary rehabilitation, symptom management, and lung transplant. Prescribed antifibrotic drugs include, Pirfenidone and Nintedanib. Request For A Sample Copy Of This
Read more